Dimensional Fund Advisors
PRLD icon

Dimensional Fund Advisors’s Prelude Therapeutics PRLD Stock Holding History

Dimensional Fund Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$187K Hold
35,210
– – ﹤0.01% 3083
2026
Q1 		$120K Buy
+35,210
New +$92.3K ﹤0.01% 3103
2025
Q1 		– Sell
-10,981
Closed -$13.9K – 3349
2024
Q4 		$13.9K Sell
10,981
-18,101
-62% -$24K ﹤0.01% 3333
2024
Q3 		$60.3K Buy
29,082
+8
+0% +$37 ﹤0.01% 3282
2024
Q2 		$111K Buy
29,074
+14,769
+103% +$60.1K ﹤0.01% 3239
2024
Q1 		$67.8K Hold
14,305
– – ﹤0.01% 3310
2023
Q4 		$60.9K Buy
14,305
+3,117
+28% +$9.49K ﹤0.01% 3335
2023
Q3 		$34.5K Sell
11,188
-2,943
-21% -$11K ﹤0.01% 3408
2023
Q2 		$63.6K Buy
14,131
+1,372
+11% +$8.2K ﹤0.01% 3384
2023
Q1 		$72.7K Buy
+12,759
New +$77.8K ﹤0.01% 3352
2022
Q3 		$97K Buy
+14,616
New +$98.5K ﹤0.01% 3338

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Dimensional Fund Advisors's PRLD Position: Q2 2026 in Review

Dimensional Fund Advisors held its Prelude Therapeutics (PRLD) position steady in Q2 2026 at 35,210 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #3083.

Dimensional Fund Advisors first reported a position in PRLD in Q3 2022 and has held it in 11 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Dimensional Fund Advisors held 35,210 shares of Prelude Therapeutics worth $187K as of Q2 2026.
  • Dimensional Fund Advisors left its Prelude Therapeutics share count unchanged in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #3083 holding.
  • Dimensional Fund Advisors first reported a position in Prelude Therapeutics in Q3 2022 and has held it in 11 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.